ClinicalTrials.gg

Program

muvalaplin

Also written as “LY3473329”, “[14C]-LY3473329” and “Muvalaplin”.

Its studies are mostly in Atherosclerosis · Renal Insufficiency, led by Eli Lilly.

Furthest: phase 3, since Aug 28, 20256 company-led studies, 1 open or runningNext primary completion: Mar 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly61 open or runningphase 3since Aug 28, 2025Jul 14, 2020Mar 2031phase 3 · NCT07157774
  • Named in Eli Lilly’s own pipeline as Muvalaplin, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2020First study: phase 1 study in HealthyFirst studyNCT04472676 · 86 enrolled · Netherlands
  2. Sep 7, 2021Phase 1 study in HealthyNCT05038787 · 24 enrolled · United States
  3. Sep 28, 2022Phase 2 study in AtherosclerosisNCT05563246 · 233 enrolled · United States, Australia, Brazil and more
  4. Mar 10, 2023Phase 1 study in Renal InsufficiencyNCT05778864 · 47 enrolled · United States
  5. Feb 26, 2024Phase 1 study in HealthyNCT06342596 · 16 enrolled · United Kingdom
  6. Aug 28, 2025Phase 3 study in AtherosclerosisNCT07157774 · 10,450 planned · United States, Argentina, Australia and more

Ahead

  1. Mar 2031Primary completion: phase 3 study in AtherosclerosisNCT07157774

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07157774Atherosclerosis · United States, Argentina, Australia and more3RecruitingMar 203110,450
NCT06342596Healthy · United Kingdom1CompletedMay 1, 202416
NCT05778864Renal Insufficiency · United States1CompletedSep 6, 202447
NCT05563246Atherosclerosis · United States, Australia, Brazil and more2CompletedMar 14, 2024233
NCT05038787Healthy · United States1CompletedApr 7, 202224
NCT04472676Healthy · Netherlands1CompletedNov 9, 202186

How it is read

Names in the registry

  • “LY3473329”, 5 entries
  • “[14C]-LY3473329”, 2 entries
  • “Muvalaplin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.